Abstract：Objective To investigate the value of serum miR-143 level combined with MRI in predicting the early response to concurrent chemoradiotherapy (CCRT) in cervical cancer. Methods A total of 85 patients with pathologically confirmed cervical cancer underwent conventional MRI, intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI), and dynamic contrast-enhanced MRI (DCE-MRI) before CCRT. The biopsy tissues and serum samples were collected. The differential expression of miRNA in the biopsy tissues was determined by microarray chip. The expression level of miR-143 in the serum samples was analyzed by qRT-PCR. All patients were divided into the non-residual and residual tumor groups according to post-treatment MRI. Pre-treatment clinical factors, MRI parameters and miR-143 between two groups were statistically analyzed by the univariate and multivariate analyses. The optimal thresholds and predictive performance for post-treatment incidence of residual tumors were estimated by drawing the ROC curve. Results At one month after CCRT, there were 52 patients in the non-residual tumor group and 33 patients in the residual tumor group. In the residual tumor group, pre-treatment FIGO staging, apparent diffusion coefficient (ADC), D and Ve were significantly higher (all P<0.05), whereas Ktrans value was significantly lower (P<0.001) when compared to those in the non-residual tumor group. The miRNA array analysis showed that there were 16 miRNAs with differential expression levels between two groups (all P<0.05). Among them, the increase of miR-143 was the most significant in the residual tumor group. Compared with the residual tumor group, the expression level of serum miR-143 was significantly down-regulated in the non-residual tumor group (P=0.002). Compared with the SiHa cells, the expression level of miR-143 in the SiHa-R cells was significantly up-regulated (P<0.05). Multivariate analysis showed that only miR-143, D, Ktrans and Ve were the independent prognostic factors. The combination of multi-parametric MRI and miR-143 exhibited the highest predictive performance (AUC=0.975), with a sensitivity of 84.8% and a specificity of 96.2%. Conclusion The combination of multi-parametric MRI with miR-143 further improves the predictive performance for residual tumors after CCRT, which contributes to the personalized treatment of cervical cancer.
Chen Cuiyun,Wang Meiyun,Zhu Qingyao et al. The value of circulating miR-143 level in predicting early response to concurrent chemoradiotherapy in cervical cancer patients[J]. Chinese Journal of Radiation Oncology, 2021, 30(9): 910-916.
[1] Liu YM, Ni LQ, Wang SS, et al.Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy:a retrospective study[J]. World J Surg Oncol, 2018, 16(1):18.DOI:10.1186/s12957-017-1307-0. [2] 李靖,金荣,张宏凯,等.体素内不相干运动成像评估局部晚期宫颈癌同步放化疗疗效的价值[J]. 中华放射学杂志,2018, 52(3):192-198.DOI:10.3760/cma.j.issn.1005-1201.2018.03.007. Li J, Qu JR, Zhang HK, et al.Value of introvoxel incoherent motion imaging on evaluating concurrent chemoradiotherapy responsein patients with advance duter inecervix cancer[J]. Chin J Radiol, 2018, 52(3):192-198.DOI:10.3760/cma.j.issn.1005-1201.2018.03.007. [3] 狄文,余敏华.局部晚期宫颈癌术前治疗方法选择[J]. 中国实用妇科与产科杂志,2018, 34(11):1190-1193.DOI:10.19538/j.fk2018110102. Di W, Yu MH.Preoperative treatments for locally advanced cervical cancer[J]. Chin J Pract Gynecol Obstetr, 2018, 34(11):1190-1193.DOI:10.19538/j.fk2018110102. [4] Lalchandani UR, Sahai V, Hersberger K, et al.A radiologist's guide to response evaluation criteria in solid tumors[J]. Curr Probl Diagn Radiol, 2019, 48(6):576-585.DOI:10.1067/j.cpradiol.2018.07.016. [5] Latifkar A, Cerione RA, Antonyak MA.Probing the mechanisms of extracellular vesicle biogenesis and function in cancer[J]. Biochem Soc Trans, 2018, 46(5):1137-1146.DOI:10.1042/BST20180523. [6] Farzanehpour M, Mozhgani SH, Jalilvand S, et al.Serum and tissue miRNAs:potential biomarkers for the diagnosis of cervical cancer[J]. Virol J, 2019, 16(1):116.DOI:10.1186/s12985-019-1220-y. [7] 郑磊,李博.细胞外囊泡生物标志物研究现状与筛选策略[J]. 中华检验医学杂志,2018, 41(11):812-816.DOI:10.3760/cma.j.issn.1009-9158.2018.11.005 Zheng L, Li B.Research progress and screening strategies for biomarkers from extracellular vesicles in human diseases[J]. Chin J Lab Med, 2018, 41(11):812-816.DOI:10.3760/cma.j.issn.1009-9158.2018.11.005 [8] Hirokazu W, Morihito O, Yasushi K, et al.New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)[J]. Gan To Kagaku Ryoho, 2009, 36(13):2495-2501.DOI:10.3892/ol.2021.12817. [9] Zhang H, Zhou Y, Li J, et al.The value of DWI in predicting the response to synchronous radiochemotherapy for advanced cervical carcinoma:comparison among three mathematical models[J]. Cancer Imag, 2020, 20(1):8.DOI:10.1186/s40644-019-0285-6. [10] Sanguineti G, Marzi S, Marucci L, et al.Prediction of treatment response of cervical nodes using IVIM-DWI[J]. Int J Radiat Oncol, 2016, 96(2):S69-S70.DOI:10.1016/j.ejrad.2014.02.013. [11] Wu Q, Wang Y, Shi L, et al.Intravoxel incoherent motion diffusion-weighted magnetic resonance imaging of cervical cancer with different b-values[J]. J Comput Assist Tomogr, 2017, 41(4):592-598.DOI:10.1097/RCT.0000000000000569. [12] Huang JW, Song JC, Chen T, et al.Making the invisible visible:improving detectability of MRI-invisible residual cervical cancer after conisation by DCE-MRI[J]. Clin Radiol, 2019, 74(2):166.e15-166.e21.DOI:10.1016/j.crad.2018.10.013. [13] 冯煜森,丁莹莹,张娅,等.动态增强磁共振成像在宫颈癌新辅助化疗疗效评估中的价值[J]. 实用放射学杂志,2018, 34(5):725-729.DOI:10.3969/j.issn.1002-1671.2018.05.020. Feng YS, Ding YY, Zhang Y, et al.Dynamic contrast-enhanced MRI predicts the neoadjuvant chemotherapy short-term effect in patients with cervical cancer[J]. J Pract Radiol, 2018, 34(5):725-729.DOI:10.3969/j.issn.1002-1671.2018.05.020. [14] Kim JH, Kim CK, Park BK, et al.Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy[J]. Eur Radiol, 2012, 22(11):2533-2539.DOI:10.1007/s00330-012-2504-4. [15] Yang W, Qiang JW, Tian HP, et al.Multi-parametric MRI in cervical cancer:early prediction of response to concurrent chemoradiotherapy in combination with clinical prognostic factors[J]. Eur Radiol, 2018, 28(1):437-445.DOI:10.1007/s00330-017-4989-3. [16] Wang JY, Chen LJ.The role of miRNAs in the invasion and metastasis of cervical cancer[J]. Biosci Rep, 2019, 39(3):BSR20181377.DOI:10.1042/BSR20181377. [17] S hukla V, Varghese VK, Kabekkodu SP, et al.Enumeration of deregulated miRNAs in liquid and tissue biopsies of cervical cancer[J]. Gynecol Oncol, 2019, 155(1):135-143.DOI:10.1016/j.ygyno.2019.08.012. [18] Tornesello ml, Faraonio R, Buonaguro L, et al.The role of microRNAs, long non-coding RNAs, and circular RNAs in cervical cancer[J]. Front Oncol, 2020, 10:150.DOI:10.3389/fonc.2020.00150. [19] Miao J, Regenstein JM, Xu D, et al.The roles of microRNA in human cervical cancer[J]. Arch Biochem Biophys, 2020, 690:108480.DOI:10.2174/2211536610666210604123534. [20] 宋伟国,王娟,肖卫华,等.microRNA在子宫颈癌发病机制中的作用[J]. 医学分子生物学杂志,2018, 15(4):236-241.DOI:10.3870/j.issn.1672-8009.2018.04.010. Song WG, Wang J, Xiao WH, et al.Roles of microRNA in the pathogenesis of cervical cancer[J]. J Med Molecul Biol, 2018, 15(4):236-241.DOI:10.3870/j.issn.1672-8009.2018.04.010. [21] Liu MZ, Jia JY, Wang XJ, et al.Long non-coding RNA HOTAIR promotes cervical cancer progression through regulating BCL2 via targeting miR-143-3p[J]. Cancer Biol Ther, 2018, 19(5):391-399.DOI:10.1080/15384047.2018.1423921. [22] Gomes SE, SimōesAE, Pereira DM, et al.miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells[J]. Oncotarget, 2016, 7(8):9368-9387.DOI:10.18632/oncotarget.7010.
2021, Vol. 30 
